Sterile CDMO Growth Target pharma companies seeking scalable sterile fill finish, ophthalmic formulations and lyophilized injectables can partner with Jubilant Pharmova's CDMO Sterile Injectables unit, which offers full service capabilities across multiple geographies, enabling faster time to market and reduced supply chain risk.

Radiopharma Reach Jubilant's Radiopharma business operates a US network of radiopharmacies and supply chains, presenting opportunities to co-develop and supply radiopharmaceuticals, radiopharmacy sourcing, and turnkey distribution for niche diagnostics and theranostics.

CRDMO Capabilities The CRDMO platform provides comprehensive drug discovery, development and API manufacturing with world class centers in India and France, opening doors for biotech and mid size pharma clients seeking a single partner for research and development, scale up, and global regulatory readiness.

Biologics Partnerships Strategic partnerships and expansion plans with players such as Pierre Fabre indicate a focus on biologics and antibody drug conjugates, suggesting opportunities to offer biologics development, fill finish, and API capabilities to European and global customers.

Global Footprint A diversified manufacturing footprint across regulated markets and a strong reputation as a partner of choice positions Jubilant Pharmova for large deals across geographies, enabling cross selling across radiopharma, immunotherapy, generics, and proprietary therapies.